ABT

Abbott Lab's first-quarter sales beat expectations

April 17 (Reuters) - Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

"The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses," said Chief Executive Officer Miles White.

The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.